Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

Published Date: 01 Mar 2023

United Kingdom: AstraZeneca has announced that it has received European Union (EU) approval for the immuno-oncology drug combination Imfinzi (active ingredient durvalumab) and Imjudo (tremelimumab).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

2.

Improved end-of-life conversations for cancer patients are identified by a new study.

3.

In early dementia, SSRIs enhance cognition and major depression.

4.

More pain, more gain? New biopsy technique found to improve prostate cancer detection

5.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot